News Search Results
Sep 05, 2025, 01:00 ET Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche Diagnostics
Sep 05, 2025, 01:00 ET Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche Diagnostics
Sep 04, 2025, 17:18 ET CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial
SAN CARLOS, Calif., Sept. 4, 2025 /PRNewswire/ -- CAGE Bio, a biotechnology company advancing ionic liquid–based therapies for immune-mediated skin diseases, today announced positive topline results from its double-blinded,
More news about: CAGE Bio Inc.
Sep 04, 2025, 16:01 ET AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Sep 04, 2025, 15:46 ET BiotechBeauty® Launches at Credo Beauty with Nationwide Pop-Up Series
® is a skin-improving makeup brand merging biotechnology with high-performance color. Developed through years of research, its formulas use bioengineered ingredients that support the skin's microbiome
More news about: BiotechBeauty
Sep 04, 2025, 13:24 ET EverHive Expands Into APAC, Establishing Singapore Hub to Support Regional Growth
global footprint, with programs now spanning more than 40 countries across North America, EMEA, and APAC. From biotechnology and financial services to technology and gaming, EverHive continues to deliver measurable results for industries that demand agility and innovation.
More news about: EverHive Corp
Sep 04, 2025, 11:56 ET Probiotics Market Hits USD 108 Billion in 2031, Driven by Preventive Healthcare Trends | DataM Intelligence
between food companies and biotech firms to develop advanced probiotic strains. For example, several U.S. based dairy producers have partnered with biotechnology startups in the last three months to expand their probiotic-rich product lines. The supplements sector is also witnessing heightened activity, with
More news about: DataM Intelligence 4 Market Research LLP
Sep 04, 2025, 11:42 ET MSC-Specific Cell Culture Medium Market to Reach USD 4.1 Billion by 2035, with CAGR 11.6% Driven by Regenerative Medicine and Stem Cell Therapy Growth
and xeno-free MSC-specific media dominated in 2024, ensuring higher safety and compliance for therapeutic use.By Application: Pharmaceutical & Biotechnology Companies accounted for the largest shareRegional Leadership: North America led in 2024 with market share
More news about: Vantage Market Research
Sep 04, 2025, 10:01 ET Telecom Cloud Market is Projected to Reach US$ 91.92 Billion By 2031; it is Expected To Register a CAGR of 22.4% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 04, 2025, 08:49 ET NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a definitive agreement with a single
More news about: NeuroSense
Sep 04, 2025, 08:42 ET BrainSpec and University of Minnesota Collaborate to Advance Automation in MR Spectroscopy with AutoVOI
University of Minnesota's Center for Magnetic Resonance Research Center for Magnetic Resonance Research (CMRR), funded as a Biotechnology Research Center (BTRC) by the National Center for Research Resources (NCRR) until 2012 and by the National Institute of Biomedical Imaging and Bioengineering
More news about: BrainSpec
Sep 04, 2025, 08:30 ET Advancing Gene Therapy Development with Monoclonal HEK293 Cell Isolation for Regulatory Compliance, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 04, 2025, 08:30 ET Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 04, 2025, 08:15 ET Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development
Fla., Sept. 4, 2025 /PRNewswire/ -- Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for complex neurological disorders, has appointed Scott W. Rairigh as
More news about: Psilera, Inc.
Sep 04, 2025, 08:05 ET Lactiga Wins NIH Backing for First-in-Class Breastmilk-Derived Antibody in Inflammatory Bowel Disease
BRUNSWICK, N.J., Sept. 4, 2025 /PRNewswire/ -- Lactiga US, Inc., a biotechnology company developing a first-in-class mucosal antibody, announced today it has received an award from the National Institutes of Health (NIH), National
More news about: Lactiga US, Inc.
Sep 04, 2025, 08:00 ET Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial
MONTREAL, Sept. 4, 2025 /PRNewswire/ -- Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity,
More news about: Congruence Therapeutics
Sep 04, 2025, 08:00 ET Dr Francesca Rapino of THERAtRAME SA named in Business Worldwide Magazines 2025 CEO Awards
PhD, has been recognised for her outstanding achievements in advancing oncology therapeutics through innovative approaches in the biotechnology sector. The 2025 CEO Awards celebrate exceptional leaders who are redefining industries and setting new standards in leadership,
More news about: Business Worldwide Magazine
Sep 04, 2025, 08:00 ET Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
Sept. 4, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced
More news about: Coya Therapeutics, Inc.
Sep 04, 2025, 07:58 ET VLCC Unveils The Great Indian Beauty Festival 2025 - India's Biggest Beauty Celebration of the Year
booster powered by polynucleotides and the Hymagic™-4D hyaluronic acid complex for deep hydration and tissue repair, and AnteAGE MD®, a breakthrough biotechnology treatment that uses stem cell-derived growth factors and cytokines to promote skin health and rejuvenation. Speaking on the occasion, Taniya
More news about: VLCC
Sep 04, 2025, 07:30 ET Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Sep 04, 2025, 07:00 ET Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Sep 04, 2025, 07:00 ET Syantra, Inc., announces new therapeutic division for immuno-oncology drug discovery, leveraging its patent-pending Onco-ID™ platform
CALGARY, AB, Sept. 4, 2025 /PRNewswire/ - Syantra, Inc., a biotechnology company revolutionizing cancer detection, today announced a new therapeutic division that will focus on developing first-in-class therapies to help
More news about: Syantra Inc.
Sep 04, 2025, 06:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 04, 2025, 06:30 ET Immunic to Participate in Investor and Scientific Conferences in September
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Sep 04, 2025, 06:00 ET Waterdrop Inc. Announces Second Quarter 2025 Unaudited Financial Results and a Cash Dividend
clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution
More news about: Waterdrop Inc.